澳门政府向生产商提出暂缓阿斯利康疫苗供货
《澳门电台》报道,澳门卫生局局长罗奕龙表示,特区政府已向阿斯利康疫苗生产商提出暂缓对澳供货,对方已同意。政府将审视更多相关疫苗安全性的国际报告和研究,以及不同地方的政策建议,综合分析後再考虑下一步。
阿斯利康疫苗原定预计年中抵澳。罗奕龙受访时称,世界卫生组织对是否继续使用阿斯利康疫苗未有确切讲法,按照最新建议,仍然认为接种疫苗的益处大於风险,但监於澳门已有足够的新冠疫苗供居民接种,强调目前仍有2款疫苗供居民接种,首要任务是推动更多市民接种。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.